Inflammation of adipose tissue. Is there a place for statins to correct adiposopathy?
Abstract
This review is devoted to the analysis of data on the effect of inhibitors of 3-hydroxy-3-methylglutaryl coenzymate-reductase on the endocrine function of adipose tissue in obesity. Violation of metabolism of adipose tissue, as well as the amount of fat, are a a key factor in the pathophysiology of obesity and the development of concomitant diseases. Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-kofermenta reductase (HMG-COA reductase) that catalyze the initial stage of cholesterol biosynthesis in the liver. Therefore, traditionally, the liver is considered as the main target organ for statins. The results of studies of molecular mechanisms of action of statins on carbohydrate and lipid metabolism, adipokine and inflammatory balance in adipose tissue on the example of isolated adipocytes (in vivo) and in living organism (in vitro) are presented. Effect of statins on the action of insulin, as well as the possibility of developing pathological conditions associated with insulin resistance and the development of type 2 diabetes mellitus (DM 2). The proven clinical effects of cholesterol-lowering action of statins, allow new insights and to further explore their possible impact on other links in the development of obesity, and potentially to use them as therapeutic agents for pharmacological correction of obesity and the fight against cardiovascular diseases.
About the Authors
Daria A. BorodkinaInstitute for Complex Issues of Cardiovascular Diseases; Kemerovo regional clinical hospital, Regional diabetes center
Russian Federation
MD, PhD
Olga V. Gruzdeva
Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation
MD, ScD, head of the Homeostasis Research Laboratory of the Cardiovascular Disease Diagnostics Department
Elena V. Palicheva
Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation
MD, PhD, Associate professor
Olga L. Barbarash
Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation
MD, ScD, professor, corresponding member of the Russian Academy of Sciences, Director of Institute for Complex Issues of Cardiovascular Diseases
References
1. Крысанова В.С., Журавлева М.В., Сереброва С.Ю. Социальная и экономическая значимость избыточной массы тела и ожирения в Российской Федерации. Основные подходы к лечению ожирения // Русский медицинский журнал. — 2015. — Т.23. — №26. — С.1534-1537. [Krysanova VS., Zhuravleva MV., Serebrova SYu. Sotsial'naya i ekonomicheskaya znachimost' izbytochnoi massy tela i ozhireniya v Rossiiskoi Federatsii. Osnovnye podkhody k lecheniyu ozhireniya. RMŽ. 2015;23(26):1534-1537. (In Russ.)]
2. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-977. doi: 10.1161/01.CIR.67.5.968
3. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation, World Health Organization Technical Report Series, 1998 Report No.: 894
4. Tchernof A, Després J-P. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev. 2013;93(1):359-404. doi: 10.1152/physrev.00033.2011
5. Bergman RN, Kim SP, Catalano KJ, et al. Why Visceral Fat is Bad: Mechanisms of the Metabolic Syndrome. Obesity. 2006;14(2S):16S-19S. doi: 10.1038/oby.2006.277
6. Bays HE. Adiposopathy. J Am Coll Cardiol. 2011;57(25):2461-2473. doi: 10.1016/j.jacc.2011.02.038
7. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106
8. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2013;129(25 suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a
9. Ferroni P, Basili S, Davi G. Platelet Activation, Inflammatory Mediators and Hypercholesterolemia. Curr Vasc Pharmacol. 2003;1(2):157-169. doi: 10.2174/1570161033476772
10. Бородкина Д.А., Груздева О.В., Квиткова Л.В., Барбараш О.Л. Можно ли назвать висцеральное ожирение ключевым фактором парадокса ожирения? // Проблемы Эндокринологии. – 2016. – Т.62. – №6. – C.33-39. [Borodkina DA, Gruzdeva OV, Kvitkova LV, Barbarash OL. Is visceral obesity the cause of obesity paradox? Problems of endocrinology. 2016;62(6):33-39. (In Russ.)] doi: 10.14341/probl201662633-39
11. Tsoli M, Swarbrick MM, Robertson GR. Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. Semin Cell Dev Biol. 2016;54:68-81. doi: 10.1016/j.semcdb.2015.10.039
12. SENGENÈS C, BERLAN M, DE GLISEZINSKI I, LAFONTAN M, GALITZKY J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14(10):1345-1351. doi: 10.1096/fasebj.14.10.1345
13. Gomes A, Correia G, Coelho M, et al. Dietary unsaturated fatty acids differently affect catecholamine handling by adrenal chromaffin cells. J Nutr Biochem. 2015;26(5):563-570. doi: 10.1016/j.jnutbio.2014.12.009
14. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther. 2006;111(3):893-908. doi: 10.1016/j.pharmthera.2006.02.003
15. Fielding BA, Frayn KN. Lipoprotein lipase and the disposition of dietary fatty acids. Br J Nutr. 1998;80(06):495-502. doi: 10.1017/S0007114598001585
16. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events. N Engl J Med. 2001;344(26):1959-1965. doi: 10.1056/NEJM200106283442601
17. Sacks FM, Pfeffer M a, Moye L a, et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. N Engl J Med. 1996;335(14):1001-1009. doi: 10.1056/NEJM199610033351401
18. Vega G-L, Grundy SM. Effect of Statins on Metabolism of Apo-B–Containing Lipoproteins in Hypertriglyceridemic Men. Am J Cardiol. 1998;81(4):36B-42B. doi: 10.1016/S0002-9149(98)00036-8
19. Rodríguez-Calvo R, Barroso E, Serrano L, et al. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology. 2009;49(1):106-115. doi: 10.1002/hep.22570
20. Miller G., Miller N. PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE. Lancet. 1975;305(7897):16-19. doi: 10.1016/S0140-6736(75)92376-4
21. Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol. 1996;7(4):209-216. doi: 10.1097/00041433-199608000-00007
22. Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci. 1991;88(2):434-438. doi: 10.1073/pnas.88.2.434
23. Bencharif K, Hoareau L, Murumalla RK, et al. Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes. Lipids Health Dis. 2010;9(1):75. doi: 10.1186/1476-511X-9-75
24. Krautbauer S, Neumeier M, Eisinger K, et al. LDL but not HDL increases adiponectin release of primary human adipocytes. Exp Mol Pathol. 2013;95(3):325-329. doi: 10.1016/j.yexmp.2013.10.002
25. Ishihara Y, Ohmori K, Mizukawa M, et al. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis. 2010;212(1):131-138. doi: 10.1016/j.atherosclerosis.2010.04.019
26. Alexopoulos N, Melek BH, Arepalli CD, et al. Effect of Intensive Versus Moderate Lipid-Lowering Therapy on Epicardial Adipose Tissue in Hyperlipidemic Post-Menopausal Women. J Am Coll Cardiol. 2013;61(19):1956-1961. doi: 10.1016/j.jacc.2012.12.051
27. Krysiak R, Żmuda W, Okopień B. The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: A preliminary report. Pharmacol Reports. 2014;66(5):880-884. doi: 10.1016/j.pharep.2014.05.012
28. Zhao S, Wu Z. Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits. Clin Chim Acta. 2005;360(1-2):133-140. doi: 10.1016/j.cccn.2005.04.021
29. Krysiak R, Zmuda W, Okopien B. The Effect of Simvastatin-Ezetimibe Combination Therapy on Adipose Tissue Hormones and Systemic Inflammation in Patients with Isolated Hypercholesterolemia. Cardiovasc Ther. 2014;32(2):40-46. doi: 10.1111/1755-5922.12057
30. Kaplan NM. The CARE study: a postmarketing evaluation of ramipril in 11,100 patients. Clin Ther. 1996;18(4):658-670. doi: 10.1016/S0149-2918(96)80216-5
31. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med. 1998;339(19):1349-1357. doi: 10.1056/NEJM199811053391902
32. Wallace AM, McMahon AD, Packard CJ, et al. Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001;104(25):3052-3056. doi: 10.1161/hc5001.101061
33. Downs JR, Clearfield M, Weis S, et al. Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels. JAMA. 1998;279(20):1615-1622. doi: 10.1001/jama.279.20.1615
34. PEDERSEN TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl. 2004;5(3):81-87. doi: 10.1016/j.atherosclerosissup.2004.08.027
35. Wang K, Bao L, Zhou N, et al. Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo. J Med Chem. 2018;61(8):3609-3625. doi: 10.1021/acs.jmedchem.8b00107
36. Yamada Y, Takeuchi S, Yoneda M, et al. Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol. 2017;240:332-338. doi: 10.1016/j.ijcard.2017.04.103
37. Daval M, Diot-Dupuy F, Bazin R, et al. Anti-lipolytic Action of AMP-activated Protein Kinase in Rodent Adipocytes. J Biol Chem. 2005;280(26):25250-25257. doi: 10.1074/jbc.M414222200
38. Lopez S, Peiretti F, Bonardo B, et al. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 2000;152(2):359-366. doi: 10.1016/S0021-9150(00)00454-8
39. Laumen H, Skurk T, Hauner H. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008;196(2):565-573. doi: 10.1016/j.atherosclerosis.2007.06.005
40. Wang C-Y, Liu P-Y, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37-44. doi: 10.1016/j.molmed.2007.11.004
41. Payne G, Tune J, Knudson J. Leptin-Induced Endothelial Dysfunction: A Target for Therapeutic Interventions. Curr Pharm Des. 2014;20(4):603-608. doi: 10.2174/13816128113199990017
42. Sun Y-M, Li J, Luan Y, Wang L-F. Effect of statin therapy on leptin levels in patients with coronary heart disease. Peptides. 2010;31(6):1205-1207. doi: 10.1016/j.peptides.2010.03.023
43. Bellia A, Rizza S, Lombardo MF, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223(1):197-203. doi: 10.1016/j.atherosclerosis.2012.04.015
44. Chu CH, Lee JK, Lam HC, et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes. J Endocrinol Invest. 2008;31(1):42-47. doi: 10.1007/BF03345565
45. Szotowska M, Czerwienska B, Adamczak M, et al. Effect of Low-Dose Atorvastatin on Plasma Concentrations of Adipokines in Patients with Metabolic Syndrome. Kidney Blood Press Res. 2012;35(4):226-232. doi: 10.1159/000332403
46. Singh P, Zhang Y, Sharma P, et al. Statins decrease leptin expression in human white adipocytes. Physiol Rep. 2018;6(2):e13566. doi: 10.14814/phy2.13566
47. Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7(4):304-383. doi: 10.1016/j.jacl.2013.04.001
48. Chruściel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194-208. doi: 10.1016/j.atherosclerosis.2016.07.897
49. Elfakhani M, Torabi S, Hussein D, et al. Mevalonate deprivation mediates the impact of lovastatin on the differentiation of murine 3T3-F442A preadipocytes. Exp Biol Med. 2014;239(3):293-301. doi: 10.1177/1535370213517614
50. Papathanassiou M, Nikita E, Theodossiadis P, Vergados I. Orbital metastasis secondary to breast cancer mimicking thyroid-associated ophthalmopathy. Clin Exp Optom. 2010;93(5):368-369. doi: 10.1111/j.1444-0938.2010.00494.x
51. Tomiyama K, Nishio E, Watanabe Y. Both Wortmannin and Simvastatin Inhibit the Adipogenesis in 3T3-L1 Cells During the Late Phase of Differentiation. Jpn J Pharmacol. 1999;80(4):375-378. doi: 10.1254/jjp.80.375
52. Khan T, Hamilton MP, Mundy DI, et al. Impact of Simvastatin on Adipose Tissue: Pleiotropic Effects in Vivo. Endocrinology. 2009;150(12):5262-5272. doi: 10.1210/en.2009-0603
53. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822. doi: 10.2337/dc08-9018
54. Roehrich M-E, Mooser V, Lenain V, et al. Insulin-secreting β-Cell Dysfunction Induced by Human Lipoproteins. J Biol Chem. 2003;278(20):18368-18375. doi: 10.1074/jbc.M300102200
55. Sattar N, Taskinen M-R. Statins are diabetogenic – Myth or reality? Atheroscler Suppl. 2012;13(1):1-10. doi: 10.1016/j.atherosclerosissup.2012.06.001
56. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49(8):1881-1892. doi: 10.1007/s00125-006-0269-5
57. Graham I, Atar D, Borch-Johnsen K, et al. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(2_suppl):E1-E40. doi: 10.1097/01.hjr.0000277984.31558.c4
58. Kanda M, Satoh K, Ichihara K. Effects of Atorvastatin and Pravastatin on Glucose Tolerance in Diabetic Rats Mildly Induced by Streptozotocin. Biol Pharm Bull. 2003;26(12):1681-1684. doi: 10.1248/bpb.26.1681
59. Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of Atorvastatin and Pravastatin on Signal Transduction Related to Glucose Uptake in 3T3L1 Adipocytes. J Pharmacol Sci. 2008;107(1):80-89. doi: 10.1254/jphs.FP0072403
60. Ishikawa M, Namiki A, Kubota T, et al. Effect of Pravastatin and Atorvastatin on Glucose Metabolism in NonDiabetic Patients with Hypercholesterolemia. Intern Med. 2006;45(2):51-55. doi: 10.2169/internalmedicine.45.1476
Supplementary files
Review
For citations:
Borodkina D.A., Gruzdeva O.V., Palicheva E.V., Barbarash O.L. Inflammation of adipose tissue. Is there a place for statins to correct adiposopathy? Obesity and metabolism. 2019;16(1):12-19. (In Russ.)
Views:
4360
Email this article 
